Search Results - "Ray, L I"

Renal artery stenosis treated with stent deployment: Indications, technique, and outcome for 108 patients by Rodriguez-Lopez, Julio A., Werner, Alan, Ray, Lance I., Verikokos, Christos, Torruella, Luis J., Martinez, Edward, Diethrich, Edward B.

“…From January 1993 to May 1996, 108 patients (64 men, 44 women; mean age, 72 years; age range, 37 to 87 years) underwent 125 percutaneous transluminal…”
Get full text

Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis by Labidi-Galy, S.I., Rodrigues, M., Sandoval, J.L., Kurtz, J.E., Heitz, F., Mosconi, A.M., Romero, I., Denison, U., Nagao, S., Vergote, I., Parma, G., Nøttrup, T.J., Rouleau, E., Garnier, G., El-Balat, A., Zamagni, C., Martín-Lorente, C., Pujade-Lauraine, E., Fiévet, A., Ray-Coquard, I.L.

“…In the phase III PAOLA-1 study, the addition of maintenance olaparib to bevacizumab in patients with newly diagnosed high-grade ovarian cancer (HGOC) resulted…”
Get full text

Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer by Davidson, T.M., Lebreton, C.L., Hendricksen, A.E. Wahner, Atkinson, H.J., Larson, M.C., Oberg, A.L., Provencher, D.M., Glaspy, J.A., Karlan, B.Y., Slamon, D.J., Konecny, G.E., Ray-Coquard, I.L.

“…IGF signaling has been implicated in the pathogenesis and progression of ovarian carcinoma (OC). Single agent activity and safety of ganitumab (AMG 479), a…”
Get full text

Combined percutaneous transluminal angioplasty, iliac stent deployment, and femorofemoral bypass for bilateral aortoiliac occlusive disease by LOPEZ-GALARZA, L. A, RAY, L. I, RODRIGUEZ-LOPEZ, J, DIETHRICH, E. B

“…We examine the technique of combining percutaneous transluminal angioplasty and secondary intravascular stent deployment with femorofemoral bypass graft in…”
Get full text

Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer by Konecny, G.E., Hendrickson, A.E. Wahner, Davidson, T.M., Winterhoff, B.J., Ma, S., Mahner, S., Sehouli, J., Fasching, P.A., Feisel-Schwickardi, G., Poelcher, M., Roman, L.D., Rody, A., Karlan, B.Y., Mullany, S.A., Chen, H., Ray-Coquard, I.L., Provencher, D.M., Yachnin, A., Cottu, P.H., Glaspy, J.A., Haluska, P., Slamon, D.J.

“…Insulin-like growth factor (IGF) signaling is implicated in pathogenesis and chemotherapy resistance of epithelial ovarian cancer (EOC). We explored efficacy…”
Get full text

Cabozantinib in patients with advanced osteosarcomas and Ewing sarcomas: A French Sarcoma Group (FSG)/ US National Cancer Institute phase II collaborative study by Italiano, A., Penel, N., Toulmonde, M., Bompas, E., Piperno-Neumann, S., Pulido, M., Entz-Werle, N., Le Cesne, A., Chevreau, C.M., Duffaud, F., Ray-Coquard, I.L., Bellera, C., Mathoulin-Pelissier, S., Blay, J.-Y.

Get full text

Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial by Gaillard, S., Oaknin, A., Ray-Coquard, I.L., Vergote, I.B., Scambia, G., Colombo, N., Ghamande, S.A., Soto-Matos, A., Fernandez, C.M., Kahatt, C., Gomez, J., Nieto, A., Torres, N., Pardo-Burdalo, B., Papai, Z., Kristeleit, R.S., O’Malley, D.M., Benjamin, I., Pautier, P., Lorusso, D.

Get full text

Alienor/ENGOT-ov7 randomized trial exploring weekly paclitaxel (wP) + bevacizumab (bev) vs wP alone for patients with ovarian sex cord tumors (SCT) in relapse by Ray-Coquard, I.L., Harter, P., Lorusso, D., Dalban, C., Vergote, I.B., Fujiwara, K., Gladieff, L., Lueck, H.-J., Floquet, A., Lesoin, A.F., Schnelzer, A., Pignata, S., Selle, F., Sehouli, J., Brocard, F., Mangili, G., Pautier, P., De Giorgi, U., Provansal, M., Heudel, P.-E.

Get full text

Need for a stratified analysis in stage I malignant ovarian germ cell tumors (MOGCT): Prospective survival analysis of cases collection from the French rare malignant ovarian tumors (TMRO) network & GINECO group by de la Motte Rouge, T., Derquin, F., Floquet, A., Edeline, J., Lotz, J.-P., Alexandre, J., Pautier, P., Ferron, G., Boissier, E., Lefeuvre-Plesse, C., Vegas, H., Patsouris, A., Kalbacher, E., Berton-Rigaud, D., Hardy Bessard, A.-C., Lavoué, V., Ray-Coquard, I.L.

Get full text

Correlation between an automated functional assay that predicts targeted agent (TA) sensitivity and the tumor response of the sorafenib treatment evaluated within the MOST clinical trial by Tredan, O., Zelichov, O., Barbash, Z., Daitsh, Y., Birnbaum, L., Tarcic, G., You, B., Cassier, P., de la Fouchardiere, C., Ray-Coquard, I.L., Brahmi, M., Wang, Q., Attignon, V., Baudet, C., Fournier Garin, G., Agrapart, V., Dargenio, A., Chabaud, S., Perol, D., Blay, J.-Y.

Get full text

Cellular aspects of retention and transport of inhaled soluble and insoluble actinide compounds in the rat lung by Müller, H L, Taya, A, Drosselmeyer, E, Hotz, G, Pickering, S, Ray, I L, Seidel, A, Thiele, H

“…The binding of 241Am-hydroxide polymers (as models for readily soluble actinide compounds) to the cell components of rat lung was investigated using…”
Get more information

Stenting for atherosclerotic occlusive disease of the subclavian artery by Rodriguez-Lopez, J A, Werner, A, Martinez, R, Torruella, L J, Ray, L I, Diethrich, E B

“…The purpose of this study was to evaluate the results of stenting subclavian artery pathologic lesions. Between July 1991 and December 1995, 69 patients (36…”
Get more information

Treatment of childhood dermatomyositis with high dose intravenous immunoglobulin by Vedanarayanan, Vettaikorumakankav, Subramony, Sankarasubramoney H., Ray, Linda I., Evans, Owen B.

“…Two children with chronic dermatomyositis who were treated with intravenous immunoglobulin (IVIG) for 28 and 12 months, respectively, are reported. Both…”
Get full text

Experimental comparison of the thrombogenicity of fibrin and PTFE flow surfaces by Kenny, D A, Berger, K, Walker, M W, Robel, S B, Boguslavsky, L, Ray, L I, Lischko, M M, Sauvage, L R

“…Two types of 4 mm ID prostheses were studied in the carotid arteries of the dog. These were noncrimped polypropylene-supported filamentous velour knitted…”
Get full text

Traction system unbalance problem-analysis methodologies by Shi-Lin Chen, Li, R.-J., Pao-Hsiang Hsi

“…This paper presents a novel methodology using a utility's existing software for the accurate prediction of total unbalance (UB) impact due to ac traction loads…”
Get full text

79PCell lineage context and type of genomic alteration predict for the therapeutic relevance of tyrosine kinase inhibitors in human cancers by Vanacker, H, Cassier, P A, Pérol, M, Saintigny, P, Eberst, L, Carbonnaux, M, Brahmi, M, Verlingue, L, Ray-Coquard, I L, Pérol, D, Blay, J-Y

“…Abstract Background Genomic alterations of receptor tyrosine kinases (RTK) or ligands are biomarkers for some targeted therapies in a fraction of cancers, with…”
Get full text

82PArcagen: An EORTC-SPECTA project to perform a molecular characterization of rare cancers: Results of the retrospective feasibility cohort by Vinches, M, Stevovic, A, Ray-Coquard, I L, Treilleux, I, Meeus, P, Aust, S, Floquet, A, Croce, S, Chalabreysse, L, Girard, N, Blay, J-Y, Morfouace, M

“…Abstract Background Rare cancers are defined as cancers with an incidence of < 6/100,000/year. They are under-represented in the research programs including…”
Get full text

1716PThe molecular landscape of fusion genes in endometrial stromal sarcomas include three nosological entities with different natural history by Brahmi, M, Franceschi, T, Treilleux, I, Pissaloux, D, Ray-Coquard, I L, Dufresne, A, Meeus, P, Sunyach, M-P, Marie, K, Meurgey, A, Blay, J-Y, Tirode, F

“…Abstract Background About half of ESS do not harbor a JAZF1 or YWHAE fusion and other rearrangements have already been reported. With the aim to provide a…”
Get full text

PGI6 - A Cohort Study to Access the Impact of Paediatric Use of Proton Pomp Inhibitor on the Risk of Community Acquired Infections €“ Utopie by Luu, M, LE Ray, I, Bardou, M

Get full text

A Cohort Study to Access the Impact of Paediatric Use of Proton Pomp Inhibitor on the Risk of Community Acquired Infections €“ Utopie by Luu, M, LE Ray, I, Bardou, M

Get full text